STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B

STAT PlusPharma GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B The move will grow the U.K. firm’s work in oncology, particularly in lung cancer Manage alerts for this article Email this article Share this article By Andrew JosephJune 9, 2026 Europe Correspondent Andrew Joseph[email protected]Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — GSK said Tuesday it would buy the cancer-focused biotech Nuvalent in a deal worth $10.6 billion, as the British firm continues its expansion in oncology. The deal is the latest in a run of biopharma acquisitions in recent months, as large and even midsize companies have been looking to bolster their pipelines as some of their key products face looming generic competition. The GSK-Nuvalent deal is one of the largest in the recent buying spree, and GSK’s largest in years.Advertisement GSK is paying $124 per share for Cambridge, Mass.-based Nuvalent, a 26% premium to the biotech’s average share price over the last 30 days. With the cash acquired through the deal, GSK is spending about $9.4 billion on the pickup. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In Cancer, drug development, Pharmaceuticals, STAT+ Submit a correction requestReprints Andrew Joseph Europe Correspondent Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended Health June 9, 2026 Alcohol study discarded by Trump officials is published in scientific journal Health June 8, 2026 Health workers at the epicenter of Congo’s Ebola outbreak labor with little pay or rest Advertisement Pharma June 8, 2026 STAT Plus: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials Neurotransmissions June 8, 2026 STAT Report: Dementia care’s radical new era Health Care Inc. Newsletter June 8, 2026 STAT Plus: UnitedHealthcare’s lactation billing feud, and fake strokes Subscriber Picks